A thalidomide analogue, is an anti-cancer therapy of Oncology Division

NA

Thalidomide analogue indicated for the treatment of patients with:Multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy, Low- or intermediate-1-risk myelodysplastic syndromes (MDS), Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib